Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial
Key Points
Key points are not available for this paper at this time.
Abstract
Efficacy and Mechanism Evaluation programme from the UK National Institute for Health Research.
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Perguntar à IA
Like
Bookmark
Share
View Full Paper
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial | Synapse